Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy adult male (18 -70 yrs)~2. Body weight must be ≥ 50 kg and \< 120 kg, with a body mass index (BMI) \>18 but \< 35.~3. Laboratory parameters values within the normal range~Exclusion Criteria:~1. Contraindication or hypersensitivity to receiving nilotinib~2. Smokers or those who use of tobacco products or products containing nicotine~3. A past medical history of clinically significant Electrocardiogram abnormalities or a history/family history of long QT-interval syndrome.~4. History of fainting spells.~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Nilotinib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).